CoChat

Central precocious puberty following the diagnosis and treatment of paediatric cancer and central nervous system tumours: presentation and long‐term outcomes

Open access
Chemaitilly, Wassim, Merchant, Thomas E., Li, Zhenghong, Barnes, Nicole, Armstrong, Gregory T., Ness, Kirsten K., Pui, Ching‐Hon, Kun, Larry E., Robison, Leslie L., Hudson, Melissa M., Sklar, Charles A., Gajjar, Amar · 2016 · Clinical Endocrinology
Cited by 62

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Summary: Objectives: To estimate the prevalence of central precocious puberty (CPP) after treatment for tumours and malignancies involving the central nervous system (CNS) and examine repercussions on growth and pubertal outcomes. Design: Retrospective study of patients with tumours near and/or exposed to radiotherapy to the hypothalamus/pituitary axis (HPA). Patients and Measurements: Patients with CPP were evaluated at puberty onset, completion of Gn RH agonist treatment (Gn RH a) and last follow‐up. Multivariable analysis was used to test associations between tumour location, sex, age at CPP, Gn RH a duration and a diagnosis of CPP with final height <‐2 SD score (SDS), gonadotropin deficiency (LH/FSHD) and obesity, respectively. Results: Eighty patients (47 females) had CPP and were followed for 11·4 ± 5·0 years (mean ± SD). The prevalence of CPP was 15·2% overall, 29·2% following HPA tumours and 6·6% after radiotherapy for non‐HPA tumours. Height <‐2 SDS was more common at the last follow‐up than at the puberty onset (21·4% vs 2·4%, P = 0·005). Obesity was more prevalent at the last follow‐up than at the completion of Gn RH a or the puberty onset (37·7%, 22·6% and 20·8%, respectively, P = 0·03). Longer duration of Gn RH a was associated with increased odds of final height <‐2 SDS (OR = 2·1, 95% CI 1·0–4·3) and longer follow‐up with obesity (OR = 1·3, 95% CI 1·1–1·6). LH/FSHD was diagnosed in 32·6%. There was no independent association between CPP and final height <‐2 SDS, and LH/FSHD and obesity in the subset of patients with HPA low‐grade gliomas. Conclusions: Patients with organic CPP experience an incomplete recovery of growth and a high prevalence of LH/FSHD and obesity. Early diagnosis and treatment of CPP may limit further deterioration of final height prospects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cen.12964

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 62

Metadata

Authors
Chemaitilly, W., Merchant, T. E., Li, Z., Barnes, N., Armstrong, G. T., Ness, K. K., Pui, C., Kun, L. E., Robison, L. L., Hudson, M. M., Sklar, C. A., & Gajjar, A.
Venue
Clinical Endocrinology
Publisher
Wiley
Published
2015-11-16
Volume
84
Issue
3
Pages
361-371
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
OpenAlex
W1913952946
Cited by
62
References
3
FWCI
4.59
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Central precocious puberty following the diagnosis and treatment of paediatric cancer and central nervous system tumours: presentation and long‐term outcomes. https://app.cochat.ai/papers/10.1111/cen.12964
The paper
Chemaitilly, W., Merchant, T. E., Li, Z., Barnes, N., Armstrong, G. T., Ness, K. K., Pui, C., Kun, L. E., Robison, L. L., Hudson, M. M., Sklar, C. A., & Gajjar, A. (2016). Central precocious puberty following the diagnosis and treatment of paediatric cancer and central nervous system tumours: presentation and long‐term outcomes. Clinical Endocrinology. https://doi.org/10.1111/cen.12964

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.